Leucémie myéloïde aiguë (LMA)

  • Accueil
  • Leucémie myéloïde aiguë (LMA)
  • LIVEN (P23-363)

TITRE (EN) Capturing Canadian Real-World Data for AML Chemotherapy Ineligible Patients on Venetoclax
PROTOCOLE ID LIVEN (P23-363)
CLINICAL TRIAL.gov ID NCT05424562
TYPE(S) DE CANCER Leucémie myéloïde aiguë (LMA)
PHASE Autres
TYPE D'ÉTUDE Autre
INSTITUTION CENTRE UNIVERSITAIRE DE SANTE MCGILL
1001 boul. Décarie
VILLE Montréal
INVESTIGATEUR(RICE) PRINCIPAL(E) John Storring
COORDONATEUR(RICE) Judit Kokai
judit.kokai@muhc.mcgill.ca
438-888-1582
STATUT  Actif en recrutement
CRITÈRES D'ÉLIGIBILITÉ (EN)
  • Diagnosis of Acute Myeloid Leukemia (AML).
  • Ineligible for intensive chemotherapy, determined by the physician's assessment of age, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), comorbidities, regional guidelines, and institutional practice.
  • Participant for whom the physician has decided to initiate venetoclax treatment in accordance with the local label. The decision to treat with venetoclax is made by the physician prior to any decision to approach the participant to participate in this study.
CRITÈRES D'EXCLUSION (EN)
  • Participation in an interventional clinical trial within 30 days prior to venetoclax treatment initiation.